Compare ZVRA & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZVRA | SANA |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.9M | 1.4B |
| IPO Year | 2015 | 2021 |
| Metric | ZVRA | SANA |
|---|---|---|
| Price | $9.94 | $3.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $23.00 | $7.50 |
| AVG Volume (30 Days) | 926.1K | ★ 2.1M |
| Earning Date | 06-12-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 159.21 | 17.24 |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $106,470,000.00 | N/A |
| Revenue This Year | $38.67 | N/A |
| Revenue Next Year | $53.63 | N/A |
| P/E Ratio | $7.39 | ★ N/A |
| Revenue Growth | ★ 350.91 | N/A |
| 52 Week Low | $6.19 | $1.27 |
| 52 Week High | $13.16 | $6.55 |
| Indicator | ZVRA | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 60.57 | 39.48 |
| Support Level | $8.32 | $2.85 |
| Resistance Level | $10.05 | $3.78 |
| Average True Range (ATR) | 0.46 | 0.25 |
| MACD | 0.14 | -0.06 |
| Stochastic Oscillator | 56.32 | 24.83 |
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.